Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06375941
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-05
Brief Title:
Prospective Observational Study of Localized Angiosarcoma of Any Site ProStars
Sponsor:
Italian Sarcoma Group
Organization:
Italian Sarcoma Group
Study Overview
Official Title:
Prospective Observational Study of Localized Angiosarcoma of Any Site ProStars
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ProStars
Brief Summary:
This study will be a multi-institutional prospective observational study of patients with localized primary AS of any site within ISG and RTR centers Patients will be treated according to clinical practice of the center and according to ISG clinical recommendations on localized AS
Detailed Description:
The management of localized AS remains a clinical challenge and needs to be better defined and standardized especially with regards to the role of radiation-therapy and systemic treatment Several questions about the best treatment approach to some clinical presentations remain open and would need to be answered by clinical studies Unfortunately the rarity of this histology among sarcomas makes it challenging to carry out clinical studies in all such presentations Moreover prognostic factors are lacking and differences in epidemiological pathological and clinical aspects between primary AS and secondary AS need to be better characterized
These issues may be addressed with a prospective multi-institutional observational study through the collection of clinical and pathological data of patients with localized AS
Involving all reference centres for sarcoma in Italy the Italian Sarcoma Group ISG will be the ideal network for this study with the collaboration of the Italian Rare Cancer Network RTR a 7collaborative network among Italian centres focusing on improving the quality of care of patients with rare tumors
These issues may be addressed with a prospective multi-institutional observational study through the collection of clinical and pathological data of patients with localized AS
Involving all reference centres for sarcoma in Italy the Italian Sarcoma Group ISG will be the ideal network for this study with the collaboration of the Italian Rare Cancer Network RTR a 7collaborative network among Italian centres focusing on improving the quality of care of patients with rare tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None